Adverse Drug Effect—Reactive Metabolites and Idiosyncratic Drug Reactions: Part I

Abstract

Get full access to this article

View all access options for this article.

References

Uetrecht

. Idiosyncratic drug reactions: Possible role of reactive metabolites generated by leukocytes. Pharmacol Res 1989; 6: 265–73.

Riley

Maggs

Lambert

Kitteringham

Park

. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil, and mianserin. Br J Clin Pharmacol 1988; 26: 577–88.

Kitteringham

Lambert

Maggs

Colbert

Park

. A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes. Br J Clin Pharmacol 1988; 26: 13–21.

Jones

Thor

Orrenius

. Cellular defense mechanisms against toxic substances. Arch Tox 1986; 9: 259–71.

Acosta

Mitchell

. Metabolic activation and cytotoxicity of cyclophosphamide in primary cultures of postnatal rat hepatocytes. Biochem Pharmacol 1981; 30: 3225–30.

Spielberg

Gordon

Black

Goldstein

Herlong

. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722–7.

Shear

Spielberg

. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826–32.

Riley

Kitteringham

Park

. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br J Clin Pharmacol 1989; 28: 482–7.

Adams

Vorhees

Middaugh

. Developmental neurotoxicity of anticonvulsants: Human and animal evidence on phenytoin. Neurotoxicol Teratol 1990; 12: 203–14.

10.

Jones

Lacro

Johnson

Adams

. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–6.

11.

Buehler

Delimont

Van Waes

Finnell

. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990; 322: 1567–72.

12.

Valproate, spina bifida, and birth defect registries. Lancet 1988; 2: 1404–5.

13.

Lindhout

Schmidt

. In-utero exposure to valproate and neural tube defects. Lancet 1986; 1: 1392–3.

14.

Kallen

Robert

Mastroiacovo

Martinez-Frias

Castilla

Cocchi

. Anticonvulsant drugs and malformations. Eur J Epidemiol 1989; 5: 31–6.

15.

Epilepsy and spina bifida. Drug Ther Bull 1990; 28: 59–60.

16.

Rosa

. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7.

17.

Teratogenesis with carbamazepine. Lancet 1991; 337: 1316–7.

18.

Kaneko

Otani

Fukushima

Ogawa

Nomura

Ono

. Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia 1988; 29: 459–67.

19.

Kerr

Rettie

Eddy

Loiseau

Guyot

Wilensky

. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin Pharmacol Ther 1989; 46: 82–93.

20.

Martz

Failinger

Blake

. Phenytoin teratogenesis correlation between embryopathic effect and covalent binding of putative arene oxide metabolites in gestational tissue. J Pharmacol Exp Ther 1977; 203: 231–9.

21.

Dreifuss

Santilli

Langer

Sweeney

Moline

Menander

. Valproic acid hepatic fatalities. A retrospective review. Neurology 1987; 37: 379–85.

22.

Rettie

Rettenmeier

Howald

Baillie

. Cytochrome P-450-catalyzed formation of delta-4-VPA, a toxic metabolite of valproic acid. Science 1987; 235: 890–3.

23.

Levy

Rettenmeier

Anderson

Wilensky

Friel

Baillie

. Effects of polytherapy with phenytoin, carbamazepir and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 225–35.

24.

Eadie

McKinnon

Dunstan

MacLaughlin

Dickinson

. Valproate metabolism during hepatotoxicity associated with the drug. Q J Med 1990; 77: 1229–40.

25.

Appleton

Farrell

Applegarth

Dimmick

Wong

LTK

Davidson

AGF

. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990; 17: 145–8.

26.

Woosley

Drayer

Reidenberg

Nies

Carr

Oates

. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157–9.

27.

Uetrecht

Sweetman

Woosley

Oates

. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab Dispos 1984; 12: 77–81.

28.

Uetrecht

. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 1985; 232: 420–5.

29.

Rubin

Uetrecht

Jones

. Cytotoxicity of oxidative metabolites of procainamide. J Pharmacol Exp Ther 1987; 242: 833–41.

30.

Cribb

Spielberg

. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990; 18: 784–7.

31.

Rieder

Uetrecht

Shear

Spielberg

. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988; 244: 724–8.

32.

Rieder

Uetrecht

Shear

Cannon

Miller

Spielberg

. Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286–9.

33.

Shear

Spielberg

. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol 1985; 63: 1370–2.

34.

Cribb

Miller

Leeder

Hill

Spielberg

. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 1991; 19: 900–6.

35.

Pirmohamed

Coleman

Hussain

Breckenridge

Park

. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol 1991; 32: 303–10.